HONG KONG – Shanghai Junshi Biosciences Ltd. (HKG:1877) made a strong debut on the Hong Kong Stock Exchange, helped by China's first marketing approval of a homemade PD-1 monoclonal antibody last week. The biotech company's shares finished their first day of trading, on Dec. 24, up 22.55 percent to HK$23.75 (US$3.03).